Joost Uitdehaag is an accomplished expert in oncology drug discovery, both in the antibody and small molecule field. As Head of Biology at Crossfire, he is leading the biological profiling of novel degrader antibody conjugates, that endow kinase degraders with the targeted delivery and bioavailability advantages of antibodies. Before joining Crossfire Oncology, he led early discovery teams at Schering-Plough, MSD and AstraZeneca, was founding member of an oncology-based biotech company, and chaired the development team at LAVA Therapeutics that brought the bispecific antibody LAVA-1207 into Phase I. He studied Molecular Sciences at Wageningen University and holds a Ph.D. from the University of Groningen. He is author of more than 130 publications, with a h-index 31. In his talk he will highlight the current status of BTK inhibition for the treatment of lymphomas, and present Crossfire’s CFON-026 BTK conformational disruptor programme, which can combat all clinically relevant resistance mutations.